Having -c(=x)-, Wherein X Is Chalcogen, Attached Indirectly To Ring Carbon Of The Five-membered Hetero Ring By An Acyclic Carbon Or Acyclic Carbon Chain (e.g., Indole-3-acetic Acid, Etc.) Patents (Class 548/494)
  • Patent number: 6794407
    Abstract: A method for treating circadian rhythm phase disorders is described. The invention provides methods to specifically advance or delay the phase of certain circadian rhythms in humans. The disclosed methods relate to the administration of melatonin at times determined with relation to the time of dim light endogenous melatonin onset. Embodiments capable of alleviating the effects of jet lag, winter depression and shift-work sleep disturbance are provided.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: September 21, 2004
    Assignee: Oregon Health and Sciences University
    Inventors: Alfred J. Lewy, Robert L. Sack
  • Patent number: 6781000
    Abstract: &agr;-ketoamide compounds useful for treating disorders mediated by 20S proteasome in mammals having the following formula: wherein X2 is Ar or Ar—X3 wherein X3 is is —C═O, or —CH2CO—, and wherein Ar is phenyl, substituted phenyl, indole, substituted indoles, and any other heteroaryls; R1, and R2 are each individually selected from the side chains of the known natural &agr;-amino acids and unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear, branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle substituted heterocycle, heteroaryl and substituted heteroaryl; X1 is selected from hydroxide, monoalkylamino, dialkylamino, alkoxide, arylkoxide and wherein X4 is hydroxide, arylamino, monoalkylamino, dialkylamino, alkoxide, or arylalkoxide; and R3 is selected from the known natural &agr;-amino acids, unnatural amino acids
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: August 24, 2004
    Assignee: CV Theurapeutics, Inc.
    Inventors: Lisa Wang, Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Michael M Wick
  • Publication number: 20040162329
    Abstract: A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid structural analog, either alone or in combination with another carotenoid analog, or co-antioxidant formulation. The analog or analog combination is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of ischemia-reperfusion injury. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of liver disease. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of cancer.
    Type: Application
    Filed: July 29, 2003
    Publication date: August 19, 2004
    Inventors: Samuel Fournier Lockwood, Sean O'Malley, David G. Watumull, Laura M. Hix, Henry Jackson, Geoff Nadolski
  • Publication number: 20040157841
    Abstract: Mono-acylated o-phenylendiamines derivatives of formula I 1
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Inventors: Georg Fertig, Frank Herting, Manfred Kubbies, Anja Limberg, Ulrike Reiff, Michael Weidner
  • Patent number: 6774086
    Abstract: There are described derivatives of benzoylcyclohexanediones of the formula (I) and their use as herbicides. In this formula (I), R1a, R1b, R1c, R2, R3, R4 and R5 are various radicals, X1 is a bridging atom, X2 a carbon chain and X3 a chalcogen atom.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: August 10, 2004
    Assignee: Bayer CropScience GmbH
    Inventors: Thomas Seitz, Lothar Willms, Andreas van Almsick, Hermann Bieringer, Thomas Auler, Hubert Menne
  • Publication number: 20040147584
    Abstract: 1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.
    Type: Application
    Filed: December 4, 2002
    Publication date: July 29, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Cecile Combeau, Marie-Christine Bissery, Mari-Pierre Cherrier, Thomas Caulfield, Gilles Tiraboschi
  • Publication number: 20040147580
    Abstract: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.
    Type: Application
    Filed: October 6, 2003
    Publication date: July 29, 2004
    Inventors: Walter J. Burgess, Dalia Jakas, William F Huffmann, William H Miller, Kenneth A Newlander, Mark A Seefeld, Irene N Uzinskas
  • Publication number: 20040138287
    Abstract: The present invention relates to the 5-phenyl-1H-indole derivatives of formula (I): 1
    Type: Application
    Filed: November 13, 2003
    Publication date: July 15, 2004
    Inventors: Martine Barth, Pierre Dodey, Jean-Luc Paquet
  • Patent number: 6753297
    Abstract: Indole-3-succinic acid and its derivatives are used as auxins. They are administered to plants to promote root growth.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 22, 2004
    Inventors: Charloc Hammer, Daniel Armstrong
  • Publication number: 20040116488
    Abstract: The invention formula substituted 3-alkyl and 3-arylalkyl 1H indol-1yl acetic acid derivatives which are useful as inhibitors of plasminogen activator inhibitor (PAI-1) useful for treating fibrinolytic disorders, the compounds having the structure 1
    Type: Application
    Filed: December 9, 2003
    Publication date: June 17, 2004
    Applicant: Wyeth
    Inventors: Lee Dalton Jennings, Scott Lee Kincaid
  • Patent number: 6750242
    Abstract: Compounds of Formula I wherein R1, R2, R3 and R4 are as defined in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission. The compounds of the invention enhance the efficacy of agonists at nicotinic receptors.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: June 15, 2004
    Assignee: AstraZeneca AB
    Inventors: David Gurley, Thomas Lanthorn, John Macor, James Rosamond
  • Publication number: 20040110963
    Abstract: The invention relates to novel hydrazone derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives.
    Type: Application
    Filed: November 21, 2003
    Publication date: June 10, 2004
    Inventors: Kaspar Burri, Johannes Hoffner, Khalid Islam, Seema Mukhija
  • Patent number: 6743926
    Abstract: A process for the preparation of compounds of formula (1), wherein R1 is C1-C6alkyl and X is hydrogen, a hydrocarbon radical or a cation, wherein a compound of formula (2), wherein R1 is as defined above and R2 is hydrogen or a hydrocarbon radical, is reduced, the resulting compound of formula (3) is reacted with a compound that introduces the radical of formula —CH2—COOR3, wherein R3 has the meanings given above for R2, and the resulting compound of formula (4) is reduced and optionally hydrolysed.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: June 1, 2004
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Annemarie Wolleb, Heinz Wolleb
  • Publication number: 20040092569
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: December 10, 2003
    Publication date: May 13, 2004
    Inventors: Derek Anthony Demaine, Gerard Martin Paul Giblin, Rachel Elizabeth Hosking, Graham George Adam Inglis, Xiao Qing Lewell, Simon John Fawcett MacDonald, Andrew McMurtrie Mason, Martin Edward Swarbrick
  • Patent number: 6730794
    Abstract: Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: May 4, 2004
    Assignee: The Institute for Pharmaceutical Discovery, LLC.
    Inventors: Michael Lee Jones, David Gunn, John Howard Jones, Michael C. Van Zandt
  • Publication number: 20040067988
    Abstract: This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
    Type: Application
    Filed: September 30, 2003
    Publication date: April 8, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Scott I. Klein, Kevin R. Guertin
  • Publication number: 20040063746
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with ureido and thioureido piperazine derivatives of Formula I. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Application
    Filed: July 18, 2003
    Publication date: April 1, 2004
    Inventors: Alicia Regueiro-Ren, Qiufen May Xue, John F. Kadow, Malcolm Taylor
  • Publication number: 20040034202
    Abstract: The present invention provides compounds of general formula I or II: 1
    Type: Application
    Filed: April 14, 2003
    Publication date: February 19, 2004
    Applicant: The Regents of the University of California
    Inventors: Trevor C. McMorris, Michael J. Kelner
  • Publication number: 20040034090
    Abstract: A subject-matter of the present invention is compounds of formula: 1
    Type: Application
    Filed: May 13, 2003
    Publication date: February 19, 2004
    Inventors: Francis Barth, Christian Congy, Carole Guillaumont, Murielle Rinaldi, Fabienne Vasse, Claude Vernhet
  • Publication number: 20040034217
    Abstract: Intermediates A, which are important in the whole synthesis of vindoline; and a method of synthesizing intermediates respectively represented by the general formulae B and C. By the method, the target intermediates are effectively synthesized with satisfactory reproducibility. This synthesis method is especially suitable for mass production.
    Type: Application
    Filed: March 19, 2003
    Publication date: February 19, 2004
    Inventors: Tohru Fukuyama, Hidetoshi Tokuyama
  • Publication number: 20040019083
    Abstract: The present invention provides methods for the asymmetric synthesis of (S,S,R)-(−)-actinonin and its analogs and the compounds thereby synthesized having a structural formula: 1
    Type: Application
    Filed: June 25, 2003
    Publication date: January 29, 2004
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: William G. Bornmann, Francis Sirotnak, Howard Scher, Ephraim Vidal, Christopher Borelle, David Scheinberg
  • Publication number: 20040010012
    Abstract: A compound of formula (I), or a salt thereof, or a solvate thereof, wherein Ra represents a group R5 which is hydrogen, alkyl or optionally substituted aryl and Rb represents a moiety of formula (a), wherein X represents a hydroxy or an alkoxy group wherein the alkyl group may be substitued or unsubstituted or X represents a group NRsRt wherein Rs and Rt each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or Rs and Rt together with the nitrogen to which they arm attached form a heterocyclic group; R1 represents an alkyl or a substituted or unsubstituted aryl group; and R2, R3 and R4 each independently represent hydrogen, alkyl, aryl or substituted aryl; R6 and R7 each independently represent hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dial
    Type: Application
    Filed: November 20, 2002
    Publication date: January 15, 2004
    Applicant: SmithKline Beecham SpA
    Inventors: Carlo Farina, Stefania Gagliardi, Guy Marguerite Marie Gerard Nadler
  • Publication number: 20030232989
    Abstract: A new process for the preparation of specific aromatic aldehydes by ozonolysis of aromatic alkenes is provided. This new process can be advantageously integrated into a synthesis of specific chiral diols using aromatic aldehydes of this type.
    Type: Application
    Filed: April 14, 2003
    Publication date: December 18, 2003
    Inventors: Stefan Antons, Joachim Rehse, Herbert Diehl, Christian Laue
  • Publication number: 20030216405
    Abstract: This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Application
    Filed: October 9, 2002
    Publication date: November 20, 2003
    Inventors: Roland Joseph Billledeau, Chris Allen Broka, Jeffrey Allen Campbell, Jian Jeffrey Chen, Sharon Marie Dankwardt, Nancy Delaet, Leslie Ann Robinson, Keith Adrian Murray Walker
  • Publication number: 20030203909
    Abstract: The present invention provides a compound represented by the formula (I) 1
    Type: Application
    Filed: April 29, 2003
    Publication date: October 30, 2003
    Inventors: Hiroyuki Ushio, Youichiro Naito, Naoki Sugiyama, Takafumi Kawaguchi, Makio Ohtsuki, Kenji Chiba
  • Patent number: 6638963
    Abstract: A method for treating circadian rhythm disorders is described. The method involves the administration of melatonin, melatonin agonists or compounds that stimulate endogenous melatonin production so that the durations of the effective plasma concentrations of melatonin, melatonin agonists or compounds that stimulate endogenous melatonin production overlap with onset or offset of pre-treatment endogenous melatonin production, to provide a circadian-rhythm phase advance or phase delay, respectively. The methods of the invention also provide for concentration and/or duration of the effective plasma concentrations of melatonin, melatonin agonists or compounds that stimulate endogenous melatonin production to be greater in the time interval between about 8 hours before the dim light endogenous melatonin onset (DLMO) to about 4 hours after DLMO than in the time interval from about 4 hours after DLMO to about 8 hours before DLMO to achieve a circadian-rhythm phase advance.
    Type: Grant
    Filed: April 29, 1997
    Date of Patent: October 28, 2003
    Assignee: Oregon Health and Science University
    Inventors: Alfred J. Lewy, Robert L. Sack
  • Publication number: 20030199568
    Abstract: The present invention relates to a new salt of perindopril and to pharmaceutical compositions containing it.
    Type: Application
    Filed: February 21, 2003
    Publication date: October 23, 2003
    Inventors: Gerard Damien, Francois Lefoulon, Bernard Marchand
  • Publication number: 20030195244
    Abstract: Indole compounds of the formula: 1
    Type: Application
    Filed: December 12, 2002
    Publication date: October 16, 2003
    Inventors: Hsing-Pang Hsieh, Jing-Ping Liou, Jang-Yang Chang, Chun-Wei Chang
  • Publication number: 20030187053
    Abstract: The invention relates to triamide MTP/ApoB inhibitors of the formula 1 1
    Type: Application
    Filed: June 20, 2002
    Publication date: October 2, 2003
    Applicant: Pfizer Inc.
    Inventors: Peter Bertinato, Alan E. Blize, Brian S. Bronk, Hengmiao Cheng, Jin Li, Hiep Huatan, Clive Mason
  • Publication number: 20030186896
    Abstract: &agr; crystalline form of the compound of formula (I): 1
    Type: Application
    Filed: December 31, 2002
    Publication date: October 2, 2003
    Inventors: Bruno Pfeiffer, Yves-Michel Ginot, Gerard Coquerel, Stephane Beilles
  • Publication number: 20030181499
    Abstract: A compound of the formula: 1
    Type: Application
    Filed: September 30, 2002
    Publication date: September 25, 2003
    Inventors: Toshio Fujishita, Tomokazu Yoshinaga
  • Patent number: 6620947
    Abstract: Novel processes and intermediates useful in the preparation of 11-oxa prostaglandin analogs are disclosed.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: September 16, 2003
    Assignee: Alcon, Inc.
    Inventors: Pete Delgado, Raymond E. Conrow, William D. Dean, Michael S. Gaines
  • Publication number: 20030168192
    Abstract: Compounds of formula (1) containing sterically hindered groups, polymers thereof and the use of these polymers in papermaking processes and dewatering processes.
    Type: Application
    Filed: March 19, 2003
    Publication date: September 11, 2003
    Inventor: Amjad Mohmood Mohammed
  • Publication number: 20030166946
    Abstract: A process for the preparation of compounds of formula (1), wherein R1 is C1-C6alkyl and X is hydrogen, a hydrocarbon radical or a cation, wherein a compound of formula (2), wherein R1 is as defined above and R2 is hydrogen or a hydrocarbon radical, is reduced, the resulting compound of formula (3) is reacted with a compound that introduces the radical of formula —CH2—COOR3, wherein R3 has the meanings given above for R2, and the resulting compound of formula (4) is reduced and optionally hydrolysed.
    Type: Application
    Filed: November 22, 2002
    Publication date: September 4, 2003
    Inventors: Annemarie Wolleb, Heinz Wolleb
  • Publication number: 20030166615
    Abstract: The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.
    Type: Application
    Filed: October 19, 2002
    Publication date: September 4, 2003
    Inventors: David G. Hangauer, Moustafa E. El-Araby, Karen L. Milkiewicz
  • Publication number: 20030162724
    Abstract: The compounds of the invention are compounds represented by the following general formula (1): 1
    Type: Application
    Filed: November 27, 2002
    Publication date: August 28, 2003
    Inventors: Shinya Fujiwara, Tomokazu Ozaki, Toshiro Kozono, Kunihiro Hattori, Toru Esaki
  • Patent number: 6610702
    Abstract: The present invention comprises compounds, compositions thereof, and methods capable of delivering inositol hexaphospahte (IHP) to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: August 26, 2003
    Assignee: GMP Oxycell, Inc.
    Inventors: Jean-Marie Lehn, Yves Claude Nicolau, Stephane P. Vincent
  • Publication number: 20030158121
    Abstract: &ggr; crystalline form of the compound of formula (I): 1
    Type: Application
    Filed: December 31, 2002
    Publication date: August 21, 2003
    Inventors: Bruno Pfeiffer, Yves-Michel Ginot, Gerard Coquerel, Stephane Beilles
  • Publication number: 20030153770
    Abstract: A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: September 27, 2002
    Publication date: August 14, 2003
    Inventors: Ho-Shen Lin, Michael Enrico Richett
  • Publication number: 20030153611
    Abstract: 1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.
    Type: Application
    Filed: December 4, 2002
    Publication date: August 14, 2003
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick Mailliet, Cacile Combeau, Marie-Christine Bissery, Thomas Caulfield, Gilles Tiraboschi, Marie-Pierre Cherrier
  • Publication number: 20030153751
    Abstract: Novel compounds are disclosed which inhibit the activity of phospholipase enzymes in a mammal, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
    Type: Application
    Filed: May 8, 2002
    Publication date: August 14, 2003
    Applicant: American Home Products Corporation
    Inventors: Jasbir S. Seehra, Neelu Kaila, John C. McKew, Frank Lovering, Jean E. Bemis, YiBin Xiang
  • Publication number: 20030144339
    Abstract: A compound of formula (I) wherein: R1 is hydrogen, halo or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group or a trifluoromethyl group; R4 is a halo group or a trifluoromethyl group; R5 is hydrogen or halo; R6 is hydrogen or halo; provided that when R5 and R6 are both hydrogen, and one of R3 or R4 is chloro or fluoro, then the other is not chloro or fluoro; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonising an MCP-1 mediated effect in a warm-blooded animal such as a human being.
    Type: Application
    Filed: July 9, 2002
    Publication date: July 31, 2003
    Inventors: Alan Wellington Faull, Jason Grant Kettle
  • Publication number: 20030139379
    Abstract: Compounds having a metalloproteinase inhibitory activity, represented by the formula (I), its optically active isomers, their pharmaceutically acceptable salts, or hydrates thereof.
    Type: Application
    Filed: July 3, 2002
    Publication date: July 24, 2003
    Applicant: Shionogi & Co., Ltd.
    Inventors: Fumihiko Watanabe, Hiroshige Tsuzuki, Mitsuaki Ohtani
  • Publication number: 20030135044
    Abstract: This invention discloses novel gamma secretase inhibitors of the formula: 1
    Type: Application
    Filed: August 1, 2002
    Publication date: July 17, 2003
    Applicant: SCHERING CORPORATION
    Inventors: Theodros Asberom, Henry S. Guzik, Hubert B. Josien, Dmitri A. Pissarnitski
  • Publication number: 20030125569
    Abstract: Crystalline forms of the (3R,5S)- and the (3S,5R)-enantiomer of fluvastatin were found, referred to hereinafter as polymorphic Forms A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
    Type: Application
    Filed: October 1, 2002
    Publication date: July 3, 2003
    Inventors: Paul Adriaan Van Der Schaaf, Heinz Wolleb, Annemarie Wolleb, Claudia Marcolli, Martin Szelagiewicz, Andreas Burkhard, Beat Freiermuth
  • Publication number: 20030125371
    Abstract: This invention provides compounds of the formula: 1
    Type: Application
    Filed: June 18, 2002
    Publication date: July 3, 2003
    Applicant: Wyeth
    Inventors: Hassan Mahmoud Elokdah, Geraldine Ruth McFarlane, David Zenan Li, Lee D. Jennings, David LeRoy Crandall
  • Publication number: 20030119748
    Abstract: This invention is directed to novel (N-substituted) indole ICE/ced-3-inhibitor compounds. The invention is also directed to pharmaceutical compositions of such indole compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury.
    Type: Application
    Filed: September 30, 2002
    Publication date: June 26, 2003
    Applicant: Idun Pharmaceuticals, Inc.
    Inventors: Donald S. Karanewsky, Xu Bai
  • Patent number: 6583295
    Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: June 24, 2003
    Assignee: LEK Pharmaceuticals d.d.
    Inventor: Zlatko Pflaum
  • Publication number: 20030114511
    Abstract: The object of the invention is then to widen the field of use of N-substituted indole-3-glyoxylamides and thus to enrich the available pharmaceutical wealth. The possibility of a lower, longer-lasting and better-tolerable medication for the class of substances having antitumor action described in German Patent Application 19814 838.0 should thus be opened up. In particular, the disadvantageous development of resistance, as is known of many antitumor agents, should be circumvented.
    Type: Application
    Filed: January 27, 2000
    Publication date: June 19, 2003
    Inventors: Bernd Nickel, Gerald Bacher, Thomas Klenner, Thomas Beckers, Peter Emig, Jurgen Engel, Erik Bruyneel, Gunter Kamp, Kirsten Peters
  • Publication number: 20030114684
    Abstract: A process for the preparation of methyl 2-(3-chloropropoxy)-indole-3-carboxylate, which comprises reacting a 3-chloro-3-carboxylate indole compound with 3-chloropropanol in the presence of an acid having a pKa of from 0 to 2.
    Type: Application
    Filed: January 30, 2003
    Publication date: June 19, 2003
    Applicant: SmithKline Beecham plc
    Inventors: Michael Fedouloff, John Bryce Strachan